Recent research has made significant headway in understanding and enhancing therapies against various cancers. Key findings include the identification of DHCR24's role in lipid metabolism driving cervical cancer progression, the enhancement of triple-negative breast cancer cell apoptosis through combination therapy with Tanshinone IIA and olaparib, and mechanisms of resistance in colorectal cancer linked to mitochondrial metabolic shifts. Investigational compounds targeting CDK1/CDK2 and auranofin ligand co-therapy additionally promise novel cancer treatment avenues.